Expert Interview
A second look: Discussing Rezdiffra and various investigational agents in MASH
Ticker(s): MDGL, AKRO, ETNBInstitution: Texas Liver Institute
- Medical Director and VP of Research and Development at the Texas Liver Institute and Professor of Medicine at the University of Texas Health San Antonio.
- Manages hundreds of patients with NASH.
- Has authored over 400 peer-reviewed publications in medical journals.
What are your high-level thoughts on the competitive landscape of GLP-1 drugs in development for NASH, and how are NASH products evolving in the market?
Added By: catalin_adminHow do you expect the fibrosis impact from semaglutide to compare with other drugs like resmetirom, and what are your expectations for its clinical outcomes?
Added By: catalin_adminAssuming semaglutide shows a fibrosis improvement, how will this affect the commercial use of resmetirom and other NASH therapies such as FGF21s?
Added By: catalin_adminHow do you envision the treatment of NASH and MASH evolving over the next five years, particularly regarding polypharmacy and monotherapy with drugs like GLP-1s, FGF21s, and pan-PPARs?
Added By: catalin_adminIn the hepatitis B treatment landscape, what are your views on emerging antiviral therapies, the role of CAM inhibitors, and the future of immune-based therapies like PD-1s?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
